227 related articles for article (PubMed ID: 10971110)
41. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
Suda K; Inoshita N; Iguchi G; Fukuoka H; Takahashi M; Nishizawa H; Yamamoto M; Yamada S; Takahashi Y
Endocr J; 2013; 60(4):507-15. PubMed ID: 23291436
[TBL] [Abstract][Full Text] [Related]
42. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
43. Clinical applications of somatostatin analogs for growth hormone-secreting pituitary adenomas.
Wang JW; Li Y; Mao ZG; Hu B; Jiang XB; Song BB; Wang X; Zhu YH; Wang HJ
Patient Prefer Adherence; 2014 Jan; 8():43-51. PubMed ID: 24421637
[TBL] [Abstract][Full Text] [Related]
44. Sustained improvement in vision in a recurrent growth hormone secreting macroadenoma during treatment with octreotide in the absence of marked tumour shrinkage.
Lindsay JR; Harding JA; Ellis PK; Sheridan B; Atkinson AB
Pituitary; 2003; 6(4):209-14. PubMed ID: 15237932
[TBL] [Abstract][Full Text] [Related]
45. Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.
Yin J; Su CB; Xu ZQ; Yang Y; Ma WB; Tao W; Yang Z; Xia XW
Chin Med Sci J; 2005 Mar; 20(1):23-6. PubMed ID: 15844307
[TBL] [Abstract][Full Text] [Related]
46. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
Saveanu A; Jaquet P; Brue T; Barlier A
Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
[TBL] [Abstract][Full Text] [Related]
47. Long-term in-vitro treatment of human growth hormone (GH)-secreting pituitary adenoma cells with octreotide causes accumulation of intracellular GH and GH mRNA levels.
Hofland LJ; Velkeniers B; vd Lely AJ; van Koetsveld PM; Kazemzadeh M; Waaijers M; Hooghe-Peters EL; Lamberts SW
Clin Endocrinol (Oxf); 1992 Sep; 37(3):240-8. PubMed ID: 1424206
[TBL] [Abstract][Full Text] [Related]
48. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
[TBL] [Abstract][Full Text] [Related]
49. ACTH silent adenoma shrinking under cabergoline.
Petrossians P; Ronci N; Valdés Socin H; Kalife A; Stevenaert A; Bloch B; Tabarin A; Beckers A
Eur J Endocrinol; 2001 Jan; 144(1):51-7. PubMed ID: 11174837
[TBL] [Abstract][Full Text] [Related]
50. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
Teramoto A; Sanno N; Tahara S; Osamura YR
Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
[TBL] [Abstract][Full Text] [Related]
51. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.
Maiza JC; Vezzosi D; Matta M; Donadille F; Loubes-Lacroix F; Cournot M; Bennet A; Caron P
Clin Endocrinol (Oxf); 2007 Aug; 67(2):282-9. PubMed ID: 17524029
[TBL] [Abstract][Full Text] [Related]
52. Effect of SMS 201-995, a long-acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma.
George SR; Kovacs K; Asa SL; Horvath E; Cross EG; Burrow GN
Clin Endocrinol (Oxf); 1987 Apr; 26(4):395-405. PubMed ID: 2888549
[TBL] [Abstract][Full Text] [Related]
53. Current management of acromegaly.
Díez JJ; Iglesias P
Expert Opin Pharmacother; 2000 Jul; 1(5):991-1006. PubMed ID: 11249504
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
[TBL] [Abstract][Full Text] [Related]
55. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
[TBL] [Abstract][Full Text] [Related]
56. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
[TBL] [Abstract][Full Text] [Related]
57. [Somatostatin analogs in the clinical management of pituitary neoplasms].
Colao A; Dorato M; Pulcrano M; Rossi FW; Auriemma RS; Lombardi G; Lastoria S
Minerva Endocrinol; 2001 Sep; 26(3):181-91. PubMed ID: 11753242
[TBL] [Abstract][Full Text] [Related]
58. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas.
Cuevas-Ramos D; Fleseriu M
J Mol Endocrinol; 2014 Jun; 52(3):R223-40. PubMed ID: 24647046
[TBL] [Abstract][Full Text] [Related]
59. [Medical treatment of pituitary adenoma].
Chanson P
Rev Prat; 1996 Jun; 46(12):1509-13. PubMed ID: 8881166
[TBL] [Abstract][Full Text] [Related]
60. How effective are current therapies for acromegaly?
Freda PU
Growth Horm IGF Res; 2003 Aug; 13 Suppl A():S144-51. PubMed ID: 12914744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
